Toggle Main Menu Toggle Search

Open Access padlockePrints

Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease: protocol for a multi-centre, randomised, double blind, parallel group, placebo controlled, Phase 3 trial, The 'Exenatide-PD3' study

Lookup NU author(s): Dr Silvia Del DinORCiD, Dr Alison Yarnall, Professor Lynn Rochester

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Publication metadata

Author(s): Vijiaratnam N, Girges C, Auld G, Chau M, MacLagan K, King A, Skene SS, Chowdhury K, Hibbert S, Morris H, Limousin P, Athauda D, Carroll C, Hu MT, Silverdale M, Duncan GW, Chaudhuri R, Lo C, Del Din S, Yarnall AJ, Rochester L, Gibson R, Dickson J, Hunter R, Libri V, Foltynie T

Publication type: Article

Publication status: Published

Journal: BMJ Open

Year: 2021

Volume: 11

Issue: 5

Online publication date: 28/05/2021

Acceptance date: 12/05/2021

Date deposited: 02/06/2021

ISSN (electronic): 2044-6055

Publisher: BMJ Group

URL: https://doi.org/10.1136/bmjopen-2020-047993

DOI: 10.1136/bmjopen-2020-047993


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
16/167/19
BY-TF021
MH011

Share